Jiangxi Bio (06915) Concludes Price Stabilization Period, Over-Allotment Option Lapses

Stock News07-26

Jiangxi Bio (06915) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering applications.

The overall coordinator did not exercise the over-allotment option during the stabilization period, and the option has lapsed as of July 25, 2026. Consequently, no H-shares will be issued under the over-allotment option.

China International Capital Corporation Hong Kong Securities Limited, acting as the stabilization agent, or its affiliates or any person acting on their behalf, took the following stabilization actions during the period: an over-allotment of 5.435 million H-shares in the international offering; and continuous market purchases of a total of 5.435 million H-shares at prices ranging from HKD 7.40 to HKD 10.46 per share, to deliver to subscribers who have agreed to delayed delivery of the relevant H-shares subscribed under the global offering.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125783124?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-26 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125783124","market":"nz","top_or_hot":-1,"title":"Jiangxi Bio (06915) Concludes Price Stabilization Period, Over-Allotment Option Lapses","media":"Stock News","content":"<p><b>Jiangxi Bio</b> (<b>06915</b>) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering applications.<br><br>\nThe overall coordinator did not exercise the over-allotment option during the stabilization period, and the option has lapsed as of July 25, 2026. Consequently, no H-shares will be issued under the over-allotment option.<br><br>\n<b>China International Capital Corporation Hong Kong Securities Limited</b>, acting as the stabilization agent, or its affiliates or any person acting on their behalf, took the following stabilization actions during the period: an over-allotment of 5.435 million H-shares in the international offering; and continuous market purchases of a total of 5.435 million H-shares at prices ranging from HKD 7.40 to HKD 10.46 per share, to deliver to subscribers who have agreed to delayed delivery of the relevant H-shares subscribed under the global offering.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jiangxi Bio (06915) Concludes Price Stabilization Period, Over-Allotment Option Lapses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJiangxi Bio (06915) Concludes Price Stabilization Period, Over-Allotment Option Lapses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-26 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Jiangxi Bio</b> (<b>06915</b>) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering applications.<br><br>\nThe overall coordinator did not exercise the over-allotment option during the stabilization period, and the option has lapsed as of July 25, 2026. Consequently, no H-shares will be issued under the over-allotment option.<br><br>\n<b>China International Capital Corporation Hong Kong Securities Limited</b>, acting as the stabilization agent, or its affiliates or any person acting on their behalf, took the following stabilization actions during the period: an over-allotment of 5.435 million H-shares in the international offering; and continuous market purchases of a total of 5.435 million H-shares at prices ranging from HKD 7.40 to HKD 10.46 per share, to deliver to subscribers who have agreed to delayed delivery of the relevant H-shares subscribed under the global offering.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1125783124","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125783124","pubTimestamp":1785063851,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jiangxi Bio (06915) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物"},"translate_title":"江西生物(06915)价格稳定期结束，超额配股权失效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06915":1},"content_text":"Jiangxi Bio (06915) has announced that the price stabilization period related to its global offering concluded on July 25, 2026, which is the 30th day after the deadline for submitting Hong Kong public offering applications.\nThe overall coordinator did not exercise the over-allotment option during the stabilization period, and the option has lapsed as of July 25, 2026. Consequently, no H-shares will be issued under the over-allotment option.\nChina International Capital Corporation Hong Kong Securities Limited, acting as the stabilization agent, or its affiliates or any person acting on their behalf, took the following stabilization actions during the period: an over-allotment of 5.435 million H-shares in the international offering; and continuous market purchases of a total of 5.435 million H-shares at prices ranging from HKD 7.40 to HKD 10.46 per share, to deliver to subscribers who have agreed to delayed delivery of the relevant H-shares subscribed under the global offering.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125783124","isCrawlerRequest":true}